Market Research Report
Epiomic Epidemiology Series: Benign Prostatic Hypertrophy Forecast in 17 Major Markets 2016-2026
|Published by||Black Swan Analysis||Product code||354594|
|Published||Content info||48 Pages
Delivery time: 1-2 business days
|Epiomic Epidemiology Series: Benign Prostatic Hypertrophy Forecast in 17 Major Markets 2016-2026|
|Published: March 1, 2016||Content info: 48 Pages||
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Benign Prostatic Hypertrophy (BPH) Disease in 17 Major Markets
Benign Prostatic Hypertrophy (BPH) is a noncancerous (benign) enlargement of the prostate gland that can make urination difficult. The precise cause is not known but most likely involves changes caused by hormones, including testosterone and especially androgen dihydrotestosterone.
The prostate enlarges over time and is regarded as a normal aging process, with BPH being found to be common in males over the age of 60. However, if it is left untreated symptoms may worsen and the risks of urinary tract infections (UTIs) and acute urinary retention becomes higher and may require corrective surgery.
This report provides the current male prevalent population for BPH across 17 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India, Turkey, Sweden, Canada, Australia, Denmark, South Korea, Netherlands and China) split by 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of BPH have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.